Wholesale Acquisition Cost

FDA approves Bristol Myers’ oral heart disease drug

Approvals, Boxed Warning, Bristol Myers Squibb, Cardiac Arrest, Cardiac myosin inhibitors, FDA, Genetic Inflammatory Conditions, Heart Disease, Heart Muscles, Hypertrophic cardiomyopathy (HCM), Left Ventricular Ejection Fraction (LVEF), Oral Therapy, Therapeutics, Wholesale Acquisition Cost

The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s oral heart disease drug, making Camzyos (mavacamten) the first cardiac myosin inhibitor to be permitted for use in the country.

First Antibiotic With New Mechanism of Action Approved in Almost 20 Years

Antibiotics, Approvals, Community-Acquired Bacterial Pneumonia (CABP), Emergency Departments, Emergency Rooms, European Medicines Agency (EMA), Fast Track Designation, FDA, FDA/Regulatory, Priority Review, U.S. Centers for Disease Control and Prevention, Wholesale Acquisition Cost

The U.S. FDA gave Nabriva Therapeutics a thumbs-up for the company’s oral and intravenous formulations of Xenleta (lefamulin) to treat community-acquired bacterial pneumonia in adults.

Alexion wins early U.S. approval for rare blood disorder drug

Acquisitions, Analysts, Approvals, Biotech, Blood Disorders, FDA, FDA/Regulatory, Paroxysmal Nocturnal Hemoglobinuria (PNH), Potential Blockbusters, Rare Diseases, Wholesale Acquisition Cost

The U.S. Food and Drug Administration approved Alexion Pharmaceuticals Inc.’s rare blood disorder drug Ultomiris, an early backing that also solidifies the company’s dominant market position.